Danielle Williams, MD
Family Medicine · Oakland, CANPI 1821404344
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 93.2% of it on its own, with 2 other manufacturers making up the rest.
Across 59 payments — averaging $14.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$771
- Gilead$37
- Indivior Inc.$19
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$827100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $771 |
| Gilead | 2 | $37 |
| Indivior Inc. | 1 | $19 |
How this compares
$827 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $19,552 |
| TrulicityDulaglutide | 16 | $15,612 |
| JardianceEmpagliflozin | 14 | $11,350 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $3,353 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $1,943 |
| Gabapentin | 68 | $1,248 |
| Atorvastatin Calcium | 110 | $1,012 |
| Metoprolol Succinate | 59 | $726 |
| Ventolin HfaAlbuterol Sulfate | 12 | $668 |
| Tizanidine Hcl | 53 | $569 |
| Tamsulosin Hcl | 31 | $523 |
| Trazodone Hcl | 36 | $489 |
| Triamcinolone Acetonide | 33 | $462 |
| Omeprazole | 41 | $443 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 32 | $382 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Oakland
- Anthony JonesOakland$377K
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.